Back to Search
Start Over
Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy.
- Source :
- Leukemia & Lymphoma; Dec2020, Vol. 61 Issue 14, p3532-3533, 2p
- Publication Year :
- 2020
-
Abstract
- Originally, VEN-HMA was tested in frail and elderly patients with newly diagnosed AML who historically had a very low chance of attaining remission with available therapies [[1]], and it produced a high response rate with low treatment-related mortality. Six (40%) patients had achieved CR and 9 (60%) had achieved CRi with initial therapy, including a negative minimal residual disease (MRD-) response in 9 patients, while 4 had persistent MRD disease during therapy. [Extracted from the article]
- Subjects :
- ACUTE myeloid leukemia
INSTITUTIONAL review boards
Subjects
Details
- Language :
- English
- ISSN :
- 10428194
- Volume :
- 61
- Issue :
- 14
- Database :
- Complementary Index
- Journal :
- Leukemia & Lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 147712250
- Full Text :
- https://doi.org/10.1080/10428194.2020.1808213